BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 30270015)

  • 21. Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy.
    Bhadhuri A; Kind P; Salari P; Jungo KT; Boland B; Byrne S; Hossmann S; Dalleur O; Knol W; Moutzouri E; O'Mahony D; Murphy KD; Wisselink L; Rodondi N; Schwenkglenks M
    Health Qual Life Outcomes; 2020 Sep; 18(1):317. PubMed ID: 32993637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
    Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
    Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing.
    Zhu J; Yan XX; Liu CC; Wang H; Wang L; Cao SM; Liao XZ; Xi YF; Ji Y; Lei L; Xiao HF; Guan HJ; Wei WQ; Dai M; Chen W; Shi JF
    Qual Life Res; 2021 Mar; 30(3):841-854. PubMed ID: 32930993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychometric properties of the EQ-5D-5L in the general population of South Korea.
    Kim TH; Jo MW; Lee SI; Kim SH; Chung SM
    Qual Life Res; 2013 Oct; 22(8):2245-53. PubMed ID: 23224560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea.
    Kim SH; Kim HJ; Lee SI; Jo MW
    Qual Life Res; 2012 Aug; 21(6):1065-73. PubMed ID: 21947656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis.
    Chuang LH; Cohen AT; Agnelli G; Gumbs PD; Bauersachs R; Kroep S; Gitt AK; Monreal M; Willich SN; van Hout B
    Qual Life Res; 2019 May; 28(5):1155-1177. PubMed ID: 30607785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validity of the EQ-5D-5L and reference norms for the Spanish population.
    Hernandez G; Garin O; Pardo Y; Vilagut G; Pont À; Suárez M; Neira M; Rajmil L; Gorostiza I; Ramallo-Fariña Y; Cabases J; Alonso J; Ferrer M
    Qual Life Res; 2018 Sep; 27(9):2337-2348. PubMed ID: 29767329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).
    Yang F; Lau T; Lee E; Vathsala A; Chia KS; Luo N
    Eur J Health Econ; 2015 Dec; 16(9):1019-26. PubMed ID: 25519850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis.
    Yfantopoulos J; Chantzaras A; Kontodimas S
    Arch Dermatol Res; 2017 Jul; 309(5):357-370. PubMed ID: 28528371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The construct validity and responsiveness of the EQ-5D-5L, AQL-5D and a bespoke TTO in acute asthmatics.
    Crossman-Barnes CJ; Sach T; Wilson A; Barton G
    Qual Life Res; 2020 Mar; 29(3):619-627. PubMed ID: 31676971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
    Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Comparison of a Preliminary Version of the EQ-HWB Short and the 5-Level Version EQ-5D.
    Monteiro AL; Kuharic M; Pickard AS
    Value Health; 2022 Apr; 25(4):534-543. PubMed ID: 35279371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement properties of the EQ-5D-5L and PROPr in patients with spinal muscular atrophy.
    Xu RH; Ma B; Xin H; Zhang H; Zeng Y; Luo N; Dong D
    Health Qual Life Outcomes; 2023 Nov; 21(1):123. PubMed ID: 37968716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychometric performance of the Chichewa versions of the EQ-5D-Y-3L and EQ-5D-Y-5L among healthy and sick children and adolescents in Malawi.
    Ngwira LG; Maheswaran H; Verstraete J; Petrou S; Niessen L; Smith SC
    J Patient Rep Outcomes; 2023 Mar; 7(1):22. PubMed ID: 36892714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after.
    Miret C; Orive M; Sala M; García-Gutiérrez S; Sarasqueta C; Legarreta MJ; Redondo M; Rivero A; Castells X; Quintana JM; Garin O; Ferrer M;
    Qual Life Res; 2023 Apr; 32(4):989-1003. PubMed ID: 36630024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protocol for a national cohort study to explore the long-term clinical and patient-reported outcomes and cost-effectiveness of implant-based and autologous breast reconstruction after mastectomy for breast cancer: the brighter study.
    Johnson L; Holcombe C; O'Donoghue JM; Jeevan R; Browne J; Fairbrother P; MacKenzie M; Gulliver-Clarke C; White P; Mohiuddin S; Hollingworth W; Potter S
    BMJ Open; 2021 Aug; 11(8):e054055. PubMed ID: 34408062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing the measurement equivalence of EQ-5D-5L across different modes of administration.
    Mulhern B; O'Gorman H; Rotherham N; Brazier J
    Health Qual Life Outcomes; 2015 Nov; 13():191. PubMed ID: 26612336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L.
    Martin A; Meads D; Griffiths AW; Surr CA
    Value Health; 2019 Dec; 22(12):1417-1426. PubMed ID: 31806199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the measurement properties between a short and generic instrument, the 5-level EuroQoL Group's 5-dimension (EQ-5D-5L) questionnaire, and a longer and disease-specific instrument, the Functional Assessment of Cancer Therapy-Breast (FACT-B), in Asian breast cancer patients.
    Lee CF; Luo N; Ng R; Wong NS; Yap YS; Lo SK; Chia WK; Yee A; Krishna L; Wong C; Goh C; Cheung YB
    Qual Life Res; 2013 Sep; 22(7):1745-51. PubMed ID: 23054499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.
    Rencz F; Lakatos PL; Gulácsi L; Brodszky V; Kürti Z; Lovas S; Banai J; Herszényi L; Cserni T; Molnár T; Péntek M; Palatka K
    Qual Life Res; 2019 Jan; 28(1):141-152. PubMed ID: 30225788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.